Epidemiological aspects of transmitted HIV drug resistance

Scandinavian Journal of Infectious Diseases, Supplement

Volumn , Issue 106, 2003, Pages 17-20

  Girardi, Enrico ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; DRUG EFFICACY; EUROPE; GENETIC MARKER; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LABORATORY TEST; METHODOLOGY; MULTIDRUG RESISTANCE; NORTH AMERICA; PREVALENCE; PRIMARY INFECTION; PUBLIC HEALTH; STANDARDIZATION; VIRUS TRANSMISSION; ANTIBIOTIC RESISTANCE; COMPARATIVE STUDY; DISEASE TRANSMISSION; DRUG EFFECT; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; ITALY; MALE; MICROBIOLOGICAL EXAMINATION; PHARMACOEPIDEMIOLOGY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MICROBIAL SENSITIVITY TESTS; PHARMACOEPIDEMIOLOGY; PREVALENCE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 1242343608     PISSN: 03008878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-4.
2. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989: 246: 1155-8.
3. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K, Balfour Jr HH. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993; 328: 1163-5.
4. Masquelier B, Lemoigne E, Pellegrin I, Douard D, Sandler B, Fleury HJ. Primary infection with zidovudine-resistant HIV. N Engl J Med 1993: 329: 1123-4.
5. Ippolito G, Del Poggio P, Arici C, Gregis GP, Antonelli G, Riva E, Dianzani F. Transmission of zidovudine-resistant HIV during a bloody fight. JAMA 1994; 272: 433-4.
6. Cohen OJ, Fauci AS. Transmission of drug-resistant strains of HIV-1: unfortunate, but inevitable. Lancet 1999; 354: 697-8.
7. Trachtenberg JD, Sande MA. Emerging resistance to nonnucleoside reverse transcriptase inhibitors: a warning and a challenge. JAMA 2002; 288: 239-41.
8. Pomerantz RJ. Primary HIV-1 resistance: a new phase in the epidemic? JAMA 1999; 282: 1177-9.
9. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7: 1016-20.
10. Grant RM, Hecht FM, Warmerdam M, Liu L, Liegler T, Petropoulos CJ, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288: 181-8.
11. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344: 472-80.
12. Simon V, Vanderhoeven J, Hurley A, Ramratnam B, Louie M, Dawson K, et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 2002; 16: 1511-9.
13. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
14. Little SJ, Holte S, Routy JP, Connick E, Daar ES, Conway B, et al. Longitudinal analysis of transmitted drug resistance among recently HIV-infected subjects in North America. Antivir Ther 2002: 7: S144.
15. Routy JP, Brenner B, Bruce S, Machouf N, Spira B, Legault M, et al. Link between the declines of drug-resistance prevalence in newly infected individuals and of the proportion of patients receiving treatment in Montreal. Antivir Ther 2002; 7: S147.
16. Bennett D, Zaidi I, Heneine W, Woods T, Garcia-Lerma G, Weinstock H, et al. Prevalence of mutations associated with antiretroviral drug resistance among newly diagnosed, drug-naive men and women with HIV in ten US cities, 1997-2000. Program and abstracts of the XIV International AIDS Conference, 7-12 July 2002, Barcelona, Spain. Abstract TuOrC1190.
17. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Br Med J 2001; 322: 1087-8.
18. Fidler S, Frater J, Clarke J, Weber J. HIV-1 drug resistance in primary infections in the UK. Br Med J 2001; 323: 632.
19. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, et al., Swiss HIV Cohort Study Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-92.
20. Harzic M, Pellegrin I, Deveau C, Chaix ML, Dubeaux B, Garrigue I, Study Group. Genotypic drug resistance during PRIMO, primary infection in France HIV-1, et al. frequency and response to treatment. AIDS ; 16 1996; 2002: 793-6.
21. Violin M, Forbici F, Cozzi-Lepri A, Velleca R, Bertoli A, Riva C, et al., ICO.N.A. Study Group. Primary HIV-1 resistance in recently and chronically infected individuals of the Italian Cohort Naive for Antiretrovirals. J Biol Regul Homeost Agents 2002; 16: 37-43.
22. Tanuri A, Soares MA, Brindeiro RM, Diaz RS, Costa LJ, Sabino EC, et al. Brazilian network for drug resistance surveillance: results from the first national survey. Program and abstracts of the XIV International AIDS Conference, 7-12 July 2002, Barcelona, Spain. Abstract ThPeB7216.
23. Kijak GH, Pampuro SE, Avila MM, Zala C, Cahn P, Wainberg MA, Salomon H. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther 2001; 6: 71-7.
24. Fleury HJ, Mboup S, Delaporte E. Observatory of HIV-1 resistance in developing countries of Africa and Asia (ANRS 1257 project). Antivir Ther 2002; 7: S139.
25. Little SJ, Daar ES, Holte S, Frost S, Routy JP, Markowitz M, et al. Persistence of transmitted drug resistance among subjects with primary HIV infection not receiving antiretroviral therapy. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, 24-28 February 2002, Seattle, USA. Abstract 95.
26. Wensing AMJ, Albert J, Balotta C, Camacho R, Clotet B, Fleckenstein B, et al. Systematic surveillance of transmission of HIV resistance in Europe; the SPREAD project. Program and abstracts of the XIV International AIDS Conference, 7-12 July 2002, Barcelona, Spain. Abstract TuPeF5370.
27. Romano L, Venturi G, Vivarelli A, Galli L, Zazzi M. Detection of a drug-resistant human immunodeficiency virus variant in a newly infected heterosexual couple. Clin Infect Dis 2002; 34: 116-7.
28. Yerly S, Jost S, Telenti A, Flepp M, Kaiser L, Chave JP, et al., Swiss HIV Cohort Study (SHCS). Transmission of drug resistance: impact of primary and chronic HIV infection. Antivir Ther 2002; 7: S150.
29. Blackard JT, Cohen DE, Mayer KH. Human immunodeficiency virus superinfection and recombination: current state of-knowledge and potential clinical consequences. Clin Infect Dis 2002; 34: 1108-14.
30. Jost S, Bernard MC, Kasise L, Yerly S, Hirschel B, Goh L, Perrin L. HIV-1 super-infection: AE subtype supplanted by B subtype. Program and abstracts of the XIV International AIDS Conference, 7-12 July 2002, Barcelona, Spain. Abstract ThOrA1381.